S1610 Association of Statin Therapy With Inflammatory Bowel Disease Outcomes: A Real-World Evidence From a National Cohort

Introduction: Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder. Statins, widely used for cardiovascular prevention, exhibit anti-inflammatory and immunomodulatory properties, which may benefit IBD patients. Methods: We conducted a retrospective observational cohort study using the TriNetX U.S. Collaborative Network (2018–2024). Adult patients (≥18 years) with IBD were identified and divided into 2 cohorts: those receiving ≥1 year of statin therapy and those without statin use. Patients with prior antiplatelet/anticoagulant therapy were excluded. Propensity score matching was performed (1:1) across 21 variables. Primary outcomes included corticosteroid use and gastrointestinal hemorrhage, with all-cause mortality as a secondary outcome. Results: After matching, 35,350 patients (17,675 per cohort) were analyzed. Corticosteroid use was significantly lower in the statin group (54.2% vs 56.4%, odds ratio: 0.917, P < 0.001; hazard ratio [HR]: 0.955, 95% CI: 0.928–0.982, P = 0.001). Gastrointestinal hemorrhage occurred in 5.5% (statin) vs 5.9% (non-statin) (P = 0.148). Mortality was similar (3.9% vs 4.0%, P = 0.701). C-reactive protein levels were lower in statin users (15.83 vs 20.76 mg/L, P < 0.001). In the CD subgroup (n = 15,622), corticosteroid use was lower in statin users (53.5% vs 57.0%, HR: 0.918, P < 0.001); hemorrhage showed borderline significance (5.0% vs 5.8%, P = 0.037; HR: 0.873, P = 0.050), with no mortality difference. In UC patients (n = 21,530), corticosteroid use (52.7% vs 56.1%, HR: 0.917, P < 0.001) and hemorrhage (5.6% vs 6.5%, HR: 0.858, P = 0.006) were significantly lower in the statin group, with similar mortality (3.8% each). Conclusion: Statin use was associated with reduced corticosteroid use across all IBD types and lower gastrointestinal hemorrhage in UC and CD. These findings support a potential therapeutic role for statins in IBD management.